Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.

Publikation

Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.

Wissenschaftlicher Artikel/Review - 25.01.2023

Mohebbi Nilufar, Ritter Alexander, Wiegand Anna, Graf Nicole, Dahdal Suzan, Sidler Daniel, Arampatzis Spyridon, Hadaya Karine, Müller Thomas F, Wagner Carsten A, Wüthrich Rudolf P

Zitation

Mohebbi N, Ritter A, Wiegand A, Graf N, Dahdal S, Sidler D, Arampatzis S, Hadaya K, Müller T, Wagner C, Wüthrich R. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401:557-567.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lancet 2023; 401

Veröffentlichungsdatum

25.01.2023

eISSN (Online)

1474-547X

Seiten

557-567

Kurzbeschreibung/Zielsetzung

Metabolic acidosis is common in kidney transplant recipients and is associated with declining graft function. Sodium bicarbonate treatment effectively corrects metabolic acidosis, but no prospective studies have examined its effect on graft function. Therefore, we aimed to test whether sodium bicarbonate treatment would preserve graft function and slow the progression of estimated glomerular filtration rate (GFR) decline in kidney transplant recipients.